Infliximab: In ankylosing spondylitis

Drugs

Volumn 65, Issue 9, 2005, Pages 1283-1291

  Robinson, Dean M ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; METHOTREXATE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANKYLOSING SPONDYLITIS; ARTHRITIS; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; GANGLIONEUROMA; HEADACHE; HEPATITIS; HERPES SIMPLEX; HUMAN; LEUKOCYTOSIS; LEUKOPENIA; MYELITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PHARYNGITIS; PNEUMONIA; RASH; REVIEW; RHINITIS; SINUSITIS; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; CLINICAL TRIALS; HUMANS; SPONDYLITIS, ANKYLOSING;

EID: 22744454700     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565090-00006     Document Type: Review

References (36)

1. Sieper J, Braun J. Anti-TNF agents for the treatment of spondyloarthropathies. Expert Opin Emerg Drugs 2002; 7 (2): 235-46
2. Braun J, Sieper J. Biological therapies in the spondyloarthritides: the current state. Rheumatology (Oxford) 2004 Sep; 43 (9): 1072-84
3. European Agency for the Evaluation of Medicinal Products. Remicade [online]. Available from URL: www.emea.eu.int/humanndocs/Humans/EPAR/Remicade/ Remicade.htm [Accessed 2005 Jan 10]
4. Keating GM, Perry CM. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. Biodrugs 2002; 16 (2): 111-48
5. Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003 Sep; 62 (9): 817-24
6. Braun J, Xiang J, Brandt J, et al. Treatment of spondyloar-thropathies with antibodies against tumour necrosis factor α: first clinical and laboratory experiences. Ann Rheum Dis 2000; 59 Suppl. 1: i85-9
7. Gratacos J, Collado A, Filella X, et al. Serum cytokines (IL-6, TNF-α, IL-1β and IFN-γ) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994 Oct; 33 (10): 927-31
8. Zou JX, Braun J, Sieper J. Immunological basis for the use of TNFα-blocking agents in ankylosing spondylitis and immunological changes during treatment. Clin Exp Rheumatol 2002 Nov-Dec; 20 (6 Suppl. 28): S34-7
9. US Food and Drug Administration. Prescribing information: Remicade® (infliximab) for IV injection [online]. Available from URL: http://www.fda.gov/ cder/foi/label/2004/103772_5077_lbl.pdf [Accessed 2005 Jan 10]
10. Wagner C, Mace K, deWoody K. Infliximab treatment benefits correlate with pharmacodynamic parameters in Crohn's disease patients. Digestion 1998; 59 Suppl. 3: 124-5
11. Zou J, Rudwaleit M, Brandt J, et al. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 2003; 48 (3): 780-90
12. Baeten D, Vandooren B, De Rycke L, et al. Effect of infliximab treatment on T cell cytokine responses in spondylarthropathy: comment on the article by Zou et al. [letter]. Arthritis Rheum 2004; 50 (3): 1015-7
13. Yang C, Gu J, Rihl M, et al. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 2004 Oct; 51 (5): 691-9
14. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994 Dec; 21 (12): 2286-91
15. Vandooren B, Kruithof E, Yu DT, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor α blockade in spondylarthropathy. Arthritis Rheum 2004 Sep; 50 (9): 2942-53
16. Boyle A, Tawadros R, Zhu Y, et al. Comparative pharmacokinetics of single and multiple-dose infliximab in Crohn's disease patients [abstract no. W1349]. Gastroenterology 2002 Apr; 122 Suppl. 1: A614-5.
17. Plus poster presented at Digestive Disease Week and the 103rd Annual Meeting of the American Gastroenterological Association; 2002 May 19-23; San Francisco
18. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998 Sep; 41 (9): 1552-63
19. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002 Apr 6; 359: 1187-93
20. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005 Feb; 52 (2): 582-91
21. Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003 Apr; 48 (4): 1126-36
22. Braun J, Landewé R, Hermann K-G, et al. The effect of infliximab therapy on spinal inflammation assessed by magnetic resonance imaging in a randomized, placebo-controlled trial of 279 patients with ankylosing spondylitis [abstract no. L21]. Presented at 68th Annual Meeting of the American College of Rheumatology; 2004 Oct 16-21; San Antonio [online]. Available from URL: http://www.rheumatology.org/annual/abstracts/search.asp [Accessed 2005 May 11]
23. Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, ran-domized, placebo-controlled trial. Arthritis Rheum 2003 Aug; 48 (8): 2224-33
24. Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005 Feb; 64 (2): 229-34
25. Braun J, Baraliakos X, Brandt J, et al. Persistent clinical re-sponse to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005 May; 44 (5): 670-6
26. Baraliakos X, Brandt J, Listing J, et al. Clinical response to withdrawal of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Clin Exp Rheumatol 2004 Sep-Oct; 22 (5): 665
27. Stone M, Salonen D, Lax M, et al. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001 Jul; 28: 1605-14
28. Stone MA, Payne U, Pacheco-Tena C, et al. Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 2004 Jan; 63 (1): 84-7
29. Breban M, Vignon E, Claudepierre P, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a sixmonth open-label study. Rheumatology (Oxford) 2002 Nov; 41: 1280-5
30. Temekonidis TI, Alamanos Y, Nikas SN, et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 2003 Dec; 62 (12): 1218-20
31. Kobelt G, Andlin-Sobocki P, Brophy S, et al. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade®). Rheumatology (Oxford) 2004 Sep; 43 (9): 1158-66
32. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994 Dec; 21 (12): 2281-5
33. Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001 Aug; 44 (8): 1876-86
34. Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994 Sep; 21 (9): 1694-8
35. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-α antagonists. Drug Saf 2004; 27 (5): 307-24
36. Ferraro-Peyret C, Coury F, Tebib JG, et al. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 2004; 6 (6): R535-43